188 related articles for article (PubMed ID: 16676183)
1. DC-based vaccine loaded with acid-eluted peptides in acute myeloid leukemia: the importance of choosing the best elution method.
Delluc S; Tourneur L; Fradelizi D; Rubio MT; Marchiol-Fournigault C; Chiocchia G; Buzyn A
Cancer Immunol Immunother; 2007 Jan; 56(1):1-12. PubMed ID: 16676183
[TBL] [Abstract][Full Text] [Related]
2. Autologous peptides eluted from acute myeloid leukemia cells can be used to generate specific antileukemic CD4 helper and CD8 cytotoxic T lymphocyte responses in vitro.
Delluc S; Tourneur L; Michallet AS; Boix C; Varet B; Fradelizi D; Guillet JG; Buzyn A
Haematologica; 2005 Aug; 90(8):1050-62. PubMed ID: 16079104
[TBL] [Abstract][Full Text] [Related]
3. Dramatic efficacy improvement of a DC-based vaccine against AML by CD25 T cell depletion allowing the induction of a long-lasting T cell response.
Delluc S; Hachem P; Rusakiewicz S; Gaston A; Marchiol-Fournigault C; Tourneur L; Babchia N; Fradelizi D; Regnault A; Sang KH; Chiocchia G; Buzyn A
Cancer Immunol Immunother; 2009 Oct; 58(10):1669-77. PubMed ID: 19225777
[TBL] [Abstract][Full Text] [Related]
4. Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination.
Galea-Lauri J; Darling D; Mufti G; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2002 Aug; 51(6):299-310. PubMed ID: 12111118
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with leukemia-loaded dendritic cells eradicates residual disease and prevent relapse.
Deeb D; Gao X; Jiang H; Divine G; Dulchavsky SA; Gautam SC
J Exp Ther Oncol; 2006; 5(3):183-93. PubMed ID: 16528969
[TBL] [Abstract][Full Text] [Related]
6. Activation of autologous leukemia-specific T cells in acute myeloid leukemia: monocyte-derived dendritic cells cocultured with leukemic blasts compared with leukemia-derived dendritic cells.
Draube A; Beyer M; Wolf J
Eur J Haematol; 2008 Oct; 81(4):281-8. PubMed ID: 18573171
[TBL] [Abstract][Full Text] [Related]
7. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
8. Short-term activation induces multifunctional dendritic cells that generate potent antitumor T-cell responses in vivo.
Wurzenberger C; Koelzer VH; Schreiber S; Anz D; Vollmar AM; Schnurr M; Endres S; Bourquin C
Cancer Immunol Immunother; 2009 Jun; 58(6):901-13. PubMed ID: 18953536
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors.
Nagaraj S; Pisarev V; Kinarsky L; Sherman S; Muro-Cacho C; Altieri DC; Gabrilovich DI
J Immunother; 2007; 30(2):169-79. PubMed ID: 17471164
[TBL] [Abstract][Full Text] [Related]
10. [Ad hTRP2 - mediated immunity against melanoma is enhanced by dendritic cells pulsed with peptide].
Tan XH; Liu C; Wan YH
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):658-61. PubMed ID: 17274369
[TBL] [Abstract][Full Text] [Related]
11. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
Hao S; Yuan J; Xiang J
J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
[TBL] [Abstract][Full Text] [Related]
13. Generation of potent and specific cellular immune responses via in vivo stimulation of dendritic cells by pNGVL3-hFLex plasmid DNA and immunogenic peptides.
Fong CL; Hui KM
Gene Ther; 2002 Sep; 9(17):1127-38. PubMed ID: 12170376
[TBL] [Abstract][Full Text] [Related]
14. Fusion of dendritic cells and CD34+CD38- acute myeloid leukemia (AML) cells potentiates targeting AML-initiating cells by specific CTL induction.
Lei Z; Zhang GM; Hong M; Feng ZH; Huang B
J Immunother; 2009 May; 32(4):408-14. PubMed ID: 19342964
[TBL] [Abstract][Full Text] [Related]
15. AML-loaded DC generate Th1-type cellular immune responses in vitro.
Xing D; Decker WK; Li S; Robinson SN; Yang H; Segal H; O'Connor S; Yao X; Komanduri KV; McMannis JD; Jones RB; de Lima M; Champlin RE; Shpall EJ
Cytotherapy; 2006; 8(2):95-104. PubMed ID: 16698683
[TBL] [Abstract][Full Text] [Related]
16. [Anti-metastatic effect of vascular endothelial growth factor receptor 2 extracellular domain gene-modified dendritic cell vaccination in murine model with experimental pulmonary metastasis].
Pan JP; Weng YS; Wu QQ
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):646-9. PubMed ID: 17274366
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses.
Weigel BJ; Panoskaltsis-Mortari A; Diers M; Garcia M; Lees C; Krieg AM; Chen W; Blazar BR
Exp Hematol; 2006 Oct; 34(10):1403-12. PubMed ID: 16982333
[TBL] [Abstract][Full Text] [Related]
18. Induction of T cell-mediated immunity using a c-Myb DNA vaccine in a mouse model of colon cancer.
Williams BB; Wall M; Miao RY; Williams B; Bertoncello I; Kershaw MH; Mantamadiotis T; Haber M; Norris MD; Gautam A; Darcy PK; Ramsay RG
Cancer Immunol Immunother; 2008 Nov; 57(11):1635-45. PubMed ID: 18386000
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
Kim S; Lee JB; Lee GK; Chang J
Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
[TBL] [Abstract][Full Text] [Related]
20. Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial.
Van Driessche A; Van de Velde AL; Nijs G; Braeckman T; Stein B; De Vries JM; Berneman ZN; Van Tendeloo VF
Cytotherapy; 2009; 11(5):653-68. PubMed ID: 19530029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
